Class II recall: Baxter Healthcare Corporation: Vasopressin, in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/m

FDA has classified a recall by Baxter Healthcare Corporation as Class II, affecting Vasopressin in 0.9% Sodium Chloride Injection, 40 units per 100 mL (0.4 units/mL), supplied as a 100 mL single-dose container (NDC 0338-9647-12). The recall was initiated due to current good manufacturing practice (CGMP) deviations, as reported by FDA.

Most relevant for: Patients receiving vasopressin treatment for conditions requiring vasopressor support, such as severe hypotension or variceal bleeding

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.